Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript

Corcept Therapeutics reported Q2 2025 revenue of $194.4 million, an increase from $163.8 million year-over-year, but adjusted its full-year 2025 revenue guidance to $850-$900 million, citing persistent pharmacy capacity constraints that limited Korlym sales despite record demand. The company is onboarding a second pharmacy by Q4 to alleviate fulfillment issues. Looking ahead, Corcept anticipates FDA approval for relacorilant in hypercortisolism by December 30, projecting $3 billion to $5 billion in annual revenue from this indication alone within 3-5 years, driven by the CATALYST study's findings on a significant untapped patient population. Additionally, relacorilant demonstrated strong efficacy in the ROSELLA trial for platinum-resistant ovarian cancer, showing a 30% reduction in progression risk (HR 0.7, p=0.008) and improved overall survival without added toxicity, leading to an NDA submission and expected approval next year, with plans for broader oncology applications. While awaiting a Federal Circuit decision on its Korlym patent litigation against Teva, management asserts this outcome will not impact the substantial relacorilant revenue projections, which are the primary focus for future growth.

Analysis

Corcept Therapeutics reported strong Q2 2025 top-line growth, with revenue reaching $194.4 million, up from $163.8 million year-over-year, driven by record prescription volumes and a 49% increase in tablet shipments for its primary drug, Korlym. However, this growth was significantly constrained by pharmacy vendor capacity limitations, which management estimates had a $15 million negative impact on the quarter's revenue. Consequently, the company has modified its full-year 2025 revenue guidance to a range of $850 million to $900 million. To address the fulfillment bottleneck, a second pharmacy is being onboarded, with its impact expected in the fourth quarter. The company's strategic focus is rapidly shifting towards its next-generation cortisol modulator, relacorilant, which is positioned as a transformative asset. The CATALYST study results, now published in Diabetes Care, have substantially expanded the perceived market for hypercortisolism, underpinning management's projection of $3 billion to $5 billion in annual revenue for relacorilant in this indication alone within 3-5 years, pending its December 30 PDUFA date. Further bolstering the pipeline, the pivotal ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel reduced the risk of disease progression by 30% and improved overall survival in platinum-resistant ovarian cancer, leading to an NDA submission and a potential second blockbuster market. While awaiting a Federal Circuit decision on its Korlym patent litigation against Teva, management asserts the outcome is not critical to its long-term growth, which is predicated on the commercial success of relacorilant.

Key Decisions for Investors

• The primary investment thesis is now centered on the successful approval and commercial launch of relacorilant; therefore, the December 30 PDUFA date and early 2026 launch execution are the most critical catalysts to monitor.
• Investors should scrutinize Q3 and Q4 results for evidence that the pharmacy capacity issues are fully resolved, as persistent fulfillment challenges could temper near-term revenue and hinder the initial launch trajectory of relacorilant.
• The upcoming appellate court decision in the Teva patent case for Korlym is a near-term binary risk; a loss could create negative sentiment and stock volatility, while a win would remove a significant overhang from the legacy business.
• Monitor for updates following the company's August meeting with regulators regarding dazucorilant for ALS, as a defined regulatory path forward on the back of strong survival data could unlock significant, currently un-modeled value in the pipeline.
• Given the company's projection of a near-total patient switch from Korlym to the superior relacorilant, the oncology indication represents a purely additive, multi-billion dollar opportunity, making the ROSELLA trial's follow-up studies and regulatory progress a key secondary value driver.